Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer.
Jens
J
Huober
Otto
O
Schoch
Arnoud
A
Templeton
Christian
C
Spirig
Beat
B
Thürlimann
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000209:etiology*; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012129:Respiratory Function Tests; D013274:Stomach Neoplasms / Q000556:secondary; D014057:Tomography, X-Ray Computed
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C506643:liposomal doxorubicin; D000068258:Bevacizumab; D011092:Polyethylene Glycols; D004317:Doxorubicin